PedAM
Pediatric Disease Annotations & Medicines
| stomatitis | ||||
| Disease ID | 901 |
|---|---|
| Disease | stomatitis |
| Manually Symptom | (Waiting for update.) |
| Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:3) |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:5) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| snpId | pubmedId | geneId | geneSymbol | diseaseId | sourceId | sentence | score | Year | geneSymbol_dbSNP | CHROMOSOME | POS | REF | ALT |
| rs1051266 | 25041994 | 6573 | SLC19A1 | umls:C0038362 | BeFree | In addition, there was a trend toward reduced hematological toxicity among patients with variants of SLC19A1 G80A in treatment arm 1 (P for trend, .06) and reduced esophagitis/stomatitis noted among patients with variants of TSER in treatment arm 3 (P for trend, .06). | 0.000271442 | 2014 | SLC19A1 | 21 | 45537880 | T | C |
| rs25487 | 23375119 | 7515 | XRCC1 | umls:C0038362 | BeFree | Our investigation shows, for the first time, that patients with the XRCC1 399Arg/Gln genotype were more likely to experience severe acute dermatitis and oral mucositis. | 0.120271442 | 2013 | XRCC1 | 19 | 43551574 | T | C |
| rs34743033 | 23652803 | 7298 | TYMS | umls:C0038362 | BeFree | MTX AUC0-48h was a significant predictor of overall toxic adverse events during MTX courses (R(2) = 0.043; P < .001), whereas the thymidylate synthase rs34743033 tandem repeat polymorphism was predictive of stomatitis (R(2) = 0.018; P = .009), a frequent side effect of high-dose MTX. | 0.000271442 | 2013 | NA | NA | NA | NA | NA |
| rs386493716 | 23375119 | 7515 | XRCC1 | umls:C0038362 | BeFree | Our investigation shows, for the first time, that patients with the XRCC1 399Arg/Gln genotype were more likely to experience severe acute dermatitis and oral mucositis. | 0.120271442 | 2013 | NA | NA | NA | NA | NA |
| rs386514057 | 25041994 | 6573 | SLC19A1 | umls:C0038362 | BeFree | In addition, there was a trend toward reduced hematological toxicity among patients with variants of SLC19A1 G80A in treatment arm 1 (P for trend, .06) and reduced esophagitis/stomatitis noted among patients with variants of TSER in treatment arm 3 (P for trend, .06). | 0.000271442 | 2014 | NA | NA | NA | NA | NA |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
|---|
| (Waiting for update.) |
Chemical(Total Drugs:27) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0038362 | allopurinol | D000493 | 315-30-0 | stomatitis | MESH:D013280 | therapeutic | 6457698 | ||
| C0038362 | amsacrine | D000677 | - | stomatitis | MESH:D013280 | marker/mechanism | 2410119 | ||
| C0038362 | azacitidine | D001374 | 320-67-2 | stomatitis | MESH:D013280 | marker/mechanism | 2410119 | ||
| C0038362 | busulfan | D002066 | 55-98-1 | stomatitis | MESH:D013280 | marker/mechanism | 11019834 | ||
| C0038362 | carmustine | D002330 | 154-93-8 | stomatitis | MESH:D013280 | marker/mechanism | 10918425 | ||
| C0038362 | cyclophosphamide | D003520 | 50-18-0 | stomatitis | MESH:D013280 | marker/mechanism | 11019834 | ||
| C0038362 | cisplatin | D002945 | 15663-27-1 | stomatitis | MESH:D013280 | marker/mechanism | 985619 | ||
| C0038362 | epirubicin | D015251 | 56420-45-2 | stomatitis | MESH:D013280 | marker/mechanism | 1987737 | ||
| C0038362 | everolimus | D000068338 | - | stomatitis | MESH:D013280 | marker/mechanism | 19549709 | ||
| C0038362 | fluorouracil | D005472 | 51-21-8 | stomatitis | MESH:D013280 | marker/mechanism | 12119460 | ||
| C0038362 | leucovorin | D002955 | 1958/5/9 | stomatitis | MESH:D013280 | marker/mechanism | 12119460 | ||
| C0038362 | leucovorin | D002955 | 1958/5/9 | stomatitis | MESH:D013280 | therapeutic | 6607976 | ||
| C0038362 | gemcitabine | C056507 | 103882-84-4 | stomatitis | MESH:D013280 | marker/mechanism | 12006518 | ||
| C0038362 | methotrexate | D008727 | 1959/5/2 | stomatitis | MESH:D013280 | marker/mechanism | 1450620 | ||
| C0038362 | mitomycin | D016685 | 1950/7/7 | stomatitis | MESH:D013280 | marker/mechanism | 12119460 | ||
| C0038362 | mitoxantrone | D008942 | 65271-80-9 | stomatitis | MESH:D013280 | marker/mechanism | 1802019 | ||
| C0038362 | paclitaxel | D017239 | - | stomatitis | MESH:D013280 | marker/mechanism | 14760117 | ||
| C0038362 | phenindione | D010630 | 1983/12/5 | stomatitis | MESH:D013280 | marker/mechanism | 4248923 | ||
| C0038362 | phenytoin | D010672 | 57-41-0 | stomatitis | MESH:D013280 | marker/mechanism | 7439205 | ||
| C0038362 | sorafenib | C471405 | - | stomatitis | MESH:D013280 | marker/mechanism | 18796127 | ||
| C0038362 | tacrolimus | D016559 | 109581-93-3 | stomatitis | MESH:D013280 | marker/mechanism | 9209738 | ||
| C0038362 | temsirolimus | C401859 | - | stomatitis | MESH:D013280 | marker/mechanism | 16012795 | ||
| C0038362 | thiotepa | D013852 | 52-24-4 | stomatitis | MESH:D013280 | marker/mechanism | 10918425 | ||
| C0038362 | tretinoin | D014212 | 302-79-4 | stomatitis | MESH:D013280 | marker/mechanism | 9234591 | ||
| C0038362 | vincristine | D014750 | - | stomatitis | MESH:D013280 | marker/mechanism | 4294312 | ||
| C0038362 | vindesine | D014751 | 53643-48-4 | stomatitis | MESH:D013280 | marker/mechanism | 6249481 | ||
| C0038362 | vinorelbine | C030852 | 71486-22-1 | stomatitis | MESH:D013280 | marker/mechanism | 15493354 | ||
FDA approved drug and dosage information(Total Drugs:3) | ||||||||
|---|---|---|---|---|---|---|---|---|
| DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
| MESH:D013280 | busulfex | busulfan | 6MG/ML | INJECTABLE;INJECTION | Prescription | AP | Yes | Yes |
| MESH:D013280 | afinitor | everolimus | 5MG | TABLET;ORAL | Prescription | None | Yes | No |
| MESH:D013280 | torisel | temsirolimus | 25MG/ML (25MG/ML) | SOLUTION;INTRAVENOUS | Prescription | None | Yes | Yes |
FDA labeling changes(Total Drugs:3) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
| MESH:D013280 | 01/13/2003 | busulfex | busulfan | Part of a conditioning regimen administered prior to hematopoietic progenitor cell transplantation for a variety of malignant hematologic or non-malignant diseases | The population pharmacokinetic estimates of busulfan for clearance and volume of distribution were determined in an open-label, uncontrolled PK study in 24 pediatric patients 5 months to 16 years who received busulfan as part of a conditioning regimen administered prior to hematopoietic progenitor cell transplantation for a variety of malignant hematologic or non-malignant diseases Suggested dosing regimen | Labeling | B | - | - | - | Orphan Medical | 12/3/2002 | FALSE' |
| MESH:D013280 | 10/29/2010 | afinitor | everolimus | Treatment of patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis | Approved for treatment of patients with SEGA associated with TS An open-label, single-arm safety and efficacy trial was conducted in 28 patients 3-34 years with SEGA associated with TS Afinitor has not been studied in patients with SEGA < 3 years of ageMost common adverse reactions (incidence e30%) were stomatitis, upper respiratory tract infection, sinusitis, otitis media, and pyrexiaDose reduction and/or treatment interruption may be needed to manage adverse drug reactions Information on starting dose, therapeutic drug monitoring, clinical trial, and adverse reactions New indication | Labeling | B | - | - | - | Novartis | - | FALSE' |
| MESH:D013280 | 05/30/2012 | torisel | temsirolimus | Advanced recurrent/refractory solid tumors | Effectiveness in pediatric patients has not been established Torisel was studied in 59 patients 1 - 17 years and 12 patients 18 to 21 years in a phase 1-2 safety and exploratory pharmacodynamic study Adverse reactions were similar to those observedd in adults Information on dosing, clinical trials and PK parameters | Labeling | B | - | - | - | - | - | FALSE' |